Teresa Allende Aydillo Gomez

List of Publications by Year
in descending order

35 papers	4,466 citations	279798 23 h-index	361022 35 g-index
41 all docs	41 docs citations	41 times ranked	10831 citing authors

#	Article	IF	Citations
1	A serological assay to detect SARS-CoV-2 seroconversion in humans. Nature Medicine, 2020, 26, 1033-1036.	30.7	1,678
2	SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28344-28354.	7.1	421
3	Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. New England Journal of Medicine, 2020, 383, 2586-2588.	27.0	356
4	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	30.7	204
5	Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. Modern Pathology, 2021, 34, 1456-1467.	5.5	184
6	Immunological imprinting of the antibody response in COVID-19 patients. Nature Communications, 2021, 12, 3781.	12.8	149
7	A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Clinical Infectious Diseases, 2018, 67, 1322-1329.	5.8	145
8	Mutations in SARS-CoV-2 variants of concern link to increased spike cleavage and virus transmission. Cell Host and Microbe, 2022, 30, 373-387.e7.	11.0	138
9	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. Gastroenterology, 2021, 160, 2435-2450.e34.	1.3	118
10	Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1â€“2, a Randomized Controlled Clinical Trial. Clinical Infectious Diseases, 2017, 64, 829-838.	5.8	96
11	MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature, 2019, 567, 109-112.	27.8	91
12	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	28.9	80
13	Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clinical Microbiology and Infection, 2012, 18, 67-73.	6.0	76
14	Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. Journal of Infection, 2012, 65, 423-430.	3.3	74
15	Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients. American Journal of Transplantation, 2011, 11, 2205-2213.	4.7	45
16	Synthetically derived bat influenza A-like viruses reveal a cell type- but not species-specific tropism. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12797-12802.	7.1	41
17	Limited extent and consequences of pancreatic SARS-CoV-2 infection. Cell Reports, 2022, 38, 110508.	6.4	36
18	Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe. Clinical Microbiology and Infection, 2015, 21, 1040.e11-1040.e18.	6.0	35

#	Article	IF	Citations
19	Tissue-based SARS-CoV-2 detection in fatal COVID-19 infections: Sustained direct viral-induced damage is not necessary to drive disease progression. Human Pathology, 2021, 114, 110-119.	2.0	32
20	Immunosuppressed patients with pandemic influenza A 2009 (H1N1) virus infection. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 547-556.	2.9	31
21	Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clinical Microbiology and Infection, 2012, 18, E533-E540.	6.0	29
22	Deficient Long-Term Response to Pandemic Vaccine Results in An Insufficient Antibody Response to Seasonal Influenza Vaccination in Solid Organ Transplant Recipients. Transplantation, 2012, 93, 847-854.	1.0	27
23	Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo. Frontiers in Microbiology, 2019, 10, 2862.	3.5	27
24	Community-acquired pneumonia during the first post-pandemic influenza season: A prospective, multicentre cohort study. Journal of Infection, 2013, 67, 185-193.	3.3	25
25	Pre-existing Hemagglutinin Stalk Antibodies Correlate with Protection of Lower Respiratory Symptoms in Flu-Infected Transplant Patients. Cell Reports Medicine, 2020, 1, 100130.	6.5	18
26	Novel Bat Influenza Virus NS1 Proteins Bind Double-Stranded RNA and Antagonize Host Innate Immunity. Journal of Virology, 2015, 89, 10696-10701.	3.4	16
27	Effect of Influenza Vaccination Inducing Antibody Mediated Rejection in Solid Organ Transplant Recipients. Frontiers in Immunology, 2020, 11, 1917.	4.8	16
28	Coronavirus disease 2019 (COVID-19) hospitalized patients with acute kidney injury treated with acute peritoneal dialysis do not have infectious peritoneal dialysis effluent. Kidney International, 2020, 98, 782.	5.2	13
29	Specific Mutations in the PB2 Protein of Influenza A Virus Compensate for the Lack of Efficient Interferon Antagonism of the NS1 Protein of Bat Influenza A-Like Viruses. Journal of Virology, 2018, 92, .	3.4	11
30	Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients. Pediatric Transplantation, 2013, 17, 403-406.	1.0	9
31	Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial. Trials, 2014, 15, 338.	1.6	7
32	Humoral response to natural influenza infection in solid organ transplant recipients. American Journal of Transplantation, 2019, 19, 2318-2328.	4.7	6
33	Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies. Vaccines, 2020, 8, 666.	4.4	6
34	Obesity and Metabolic Dysregulation in Children Provide Protective Influenza Vaccine Responses. Viruses, 2022, 14, 124.	3.3	6
35	Protocol to isolate and assess spike protein cleavage in SARS-CoV-2 variants obtained from clinical COVID-19 samples. STAR Protocols, 2022, 3, 101502.	1.2	1